Human visfatin expression: Relationship to insulin sensitivity, intramyocellular lipids, and inflammation

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 2, 2007, Pages 666-672

  Varma, Vijayalakshmi ^a   Yao Borengasser, Aiwei ^a   Rasouli, Neda ^a   Bodles, Angela M ^a   Phanavanh, Bounleut ^a   Lee, Mi Jeong ^d   Starks, Tasha ^a   Kern, Leslie M ^a   Spencer III, Horace J ^b   McGehee Jr , Robert E ^c   Fried, Susan K ^d,e   Kern, Philip A ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b Department of Biostatistics ^*  (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; INSULIN; LIPID; METFORMIN; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VISFATIN;

ADIPOCYTE; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MALE; MUSCLE BIOPSY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUBCUTANEOUS FAT;

EID: 33846991610     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1303     Document Type: Article

References (30)

1. Cummings DE, Schwartz MW 2003 Genetics and pathophysiology of human obesity. Annu Rev Med 54:453-471
2. Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697-738
3. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I 2005 Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430
4. Kitani T, Okuno S, Fujisawa H 2003 Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 544: 74-78
5. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I 1994 Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor. Mol Cell Biol 14:1431-1437
6. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC 2004 Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113:1318-1327
7. Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, Verin AD, Natarajan V, Garcia JG 2005 Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res 70:142-151
8. van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG 2005 Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 97:25-34
9. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F 2002 Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32:3225-3234
10. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M 2005 Plasma visfatin concentrations and fat depot-specificmRNA expression in humans. Diabetes 54:2911-2916
11. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ 2006 Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295-299
12. Hammarstedt A, Pihlajamaki J, Rotter S, V, Gogg S, Jansson PA, Laakso M, Smith U 2006 Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 91:1181-1184
13. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B 2006 Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91:1578-1581
14. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA 2005 Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288:E930-E934
15. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA 2005 Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 54:2305-2313
16. Halvorsen YD, Bond A, Sen A, Franklin DM, Lea-Currie YR, Sujkowski D, Ellis PN, Wilkison WO, Gimble JM 2001 Thiazolidinediones and glucocorticoids synergistically induce differentiation of human adipose tissue stromal cells: biochemical, cellular, and molecular analysis. Metabolism 50:407-413
17. Bergman RN, Ider YZ, Bowden CR, Cobelli C 1979 Quantitative estimation of insulin sensitivity. Am J Physiol 236:E667-E677
18. Malenfant P, Joanisse DR, Theriault R, Goodpaster BH, Kelley DE, Simoneau JA 2001 Fat content in individual muscle fibers of lean and obese subjects. Int J Obes Relat Metab Disord 25:1316-1321
19. Kern PA, Simsolo RB, Fournier M 1999 Effect of weight loss on muscle fiber type, fiber size, capillarity, and succinate dehydrogenase activity in humans. J Clin Endocrinol Metab 84:4185-4190
20. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P 1998 Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47:913-917
21. Van Gaal LF, Wauters MA, Mertens IL, Considine RV, De Leeuw IH 1999 Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord 23(Suppl 1):29-36
22. Holness CL, da Silva RP, Fawcett J, Gordon S, Simmons DL 1993 Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family. J Biol Chem 268:9661-9666
23. Krssak M, Falk PK, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI 1999 Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42:113-116
24. Gray RE, Tanner CJ, Pories WJ, MacDonald KG, Houmard JA 2003 Effect of weight loss on muscle lipid content in morbidly obese subjects. Am J Physiol Endocrinol Metab 284:E726-E732
25. Hug C, Lodish HF 2005 Medicine. Visfatin: a new adipokine. Science 307: 366-367
26. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A 2006 Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49:744-747
27. Friedman J 2002 Fat in all the wrong places. Nature 415:268-269
28. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI 2004 Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664-671
29. Henry RR 2003 Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 25(Suppl B):B47-B63
30. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA 2002 Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791